Overview Dividends

(CMPX) Compass Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US20454B1044

Trocimig, CTX-471, CTX-8371, CTX-10726

Biotechnology
Market Cap in USD: 920m
IPO / Inception: 2021-04-05
Return 12m vs S&P 500: 135%

EPS (Earnings per Share)

EPS (Earnings per Share) of CMPX over the last years for every Quarter: "2020-12": -0.16, "2021-03": -0.14, "2021-06": -1.07, "2021-09": -0.1, "2021-12": -0.21, "2022-03": -0.07, "2022-06": -0.08, "2022-09": -0.12, "2022-12": -0.1, "2023-03": -0.06, "2023-06": -0.09, "2023-09": -0.08, "2023-12": -0.11, "2024-03": -0.08, "2024-06": -0.1, "2024-09": -0.08, "2024-12": -0.11, "2025-03": -0.12, "2025-06": -0.14, "2025-09": -0.08, "2025-12": 0,
EPS CAGR: 18.53%
EPS Trend: 7.1%
Last SUE: 3.15
Qual. Beats: 2

Revenue

Revenue of CMPX over the last years for every Quarter: 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 2.844, 2024-03: 0, 2024-06: 0.85, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: null,
Rev. CAGR: 0.00%
Rev. Trend: 8.4%
Last SUE: 0.00
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 91.7%
Value at Risk 5%th 141%
Relative Tail Risk -6.61%
Reward TTM
Sharpe Ratio 1.81
Alpha 205.39
CAGR/Max DD 0.01
Character TTM
Hurst Exponent 0.428
Beta 1.358
Beta Downside 1.515
Drawdowns 3y
Max DD 84.59%
Mean DD 52.59%
Median DD 58.77%

Description: CMPX Compass Therapeutics December 29, 2025

Compass Therapeutics (NASDAQ:CMPX) is a Boston-based, clinical-stage biotech that concentrates on antibody-based oncology therapies. Its lead candidates are tove-cimig, a DLL4/VEGF-A bispecific designed to shut down tumor angiogenesis; CTX-471, an IgG4 agonist of the T-cell co-stimulatory receptor CD137; and CTX-8371, a PD-1/PD-L1 bispecific checkpoint inhibitor. The company also maintains a broader pipeline of bispecifics targeting VEGF-A, PD-1 and other immune-modulatory pathways.

Key operational metrics (Q2 2025 filing) show ~ $68 million in cash and equivalents, a net loss of $22 million for the quarter, and an R&D spend of $15 million, reflecting its heavy investment in early-stage trials. The oncology biotech sector is benefiting from a projected $200 billion global market for bispecific antibodies by 2030, while recent FDA approvals of similar agents (e.g., tebentafusp, amivantamab) have accelerated investor interest and partnership opportunities. Compass recently entered a research collaboration with a major pharma partner to co-develop its VEGF-IO bispecific platform, potentially de-risking later-stage development and providing non-dilutive funding.

For a deeper, data-driven view of CMPX’s valuation dynamics, you might explore the analyst dashboards on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-65.8m TTM) > 0 and > 6% of Revenue (6% = 51.0k TTM)
FCFTA -0.19 (>2.0%) and ΔFCFTA 12.76pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 24.6k% (prev 3701 %; Δ 20.9kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.19 (>3.0%) and CFO -45.1m > Net Income -65.8m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 17.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (138.3m) change vs 12m ago 0.50% (target <= -2.0% for YES)
Gross Margin 56.82% (prev 74.80%; Δ -17.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 0.45% (prev 2.48%; Δ -2.03pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -17.21 (EBITDA TTM -68.8m / Interest Expense TTM -4.06m) >= 6 (WARN >= 3)

Altman Z'' -22.54

(A) 0.90 = (Total Current Assets 221.1m - Total Current Liabilities 12.4m) / Total Assets 231.3m
(B) -1.80 = Retained Earnings (Balance) -415.5m / Total Assets 231.3m
warn (B) unusual magnitude: -1.80 — check mapping/units
(C) -0.37 = EBIT TTM -69.9m / Avg Total Assets 190.2m
(D) -19.18 = Book Value of Equity -415.1m / Total Liabilities 21.6m
Total Rating: -22.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 32.59

1. Piotroski 0.0pt
2. FCF Yield -6.35%
3. FCF Margin data missing
4. Debt/Equity 0.05
5. Debt/Ebitda 0.53
6. ROIC - WACC (= -63.02)%
7. RoE -48.90%
8. Rev. Trend 8.37%
9. EPS Trend 7.14%

What is the price of CMPX shares?

As of January 09, 2026, the stock is trading at USD 5.17 with a total of 1,780,678 shares traded.
Over the past week, the price has changed by +0.00%, over one month by -3.54%, over three months by +32.56% and over the past year by +177.96%.

Is CMPX a buy, sell or hold?

Compass Therapeutics has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy CMPX.
  • Strong Buy: 7
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the CMPX price?

Issuer Target Up/Down from current
Wallstreet Target Price 12.6 144.1%
Analysts Target Price 12.6 144.1%
ValueRay Target Price 6.1 17.4%

CMPX Fundamental Data Overview January 04, 2026

P/S = 439.2487
P/B = 4.5566
Beta = 1.255
Revenue TTM = 850.0k USD
EBIT TTM = -69.9m USD
EBITDA TTM = -68.8m USD
Long Term Debt = 9.87m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 633.0k USD (from shortTermDebt, last quarter)
Debt = 9.87m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -36.3m USD (from netDebt column, last quarter)
Enterprise Value = 709.5m USD (919.5m + Debt 9.87m - CCE 219.9m)
Interest Coverage Ratio = -17.21 (Ebit TTM -69.9m / Interest Expense TTM -4.06m)
FCF Yield = -6.35% (FCF TTM -45.1m / Enterprise Value 709.5m)
FCF Margin = -5303 % (FCF TTM -45.1m / Revenue TTM 850.0k)
Net Margin = -7742 % (Net Income TTM -65.8m / Revenue TTM 850.0k)
Gross Margin = 56.82% ((Revenue TTM 850.0k - Cost of Revenue TTM 367.0k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.07 (Enterprise Value 709.5m / Total Assets 231.3m)
Interest Expense / Debt = 18.99% (Interest Expense 1.87m / Debt 9.87m)
Taxrate = -0.0% (0.0 / -49.4m)
NOPAT = -69.9m (EBIT -69.9m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 17.82 (Total Current Assets 221.1m / Total Current Liabilities 12.4m)
Debt / Equity = 0.05 (Debt 9.87m / totalStockholderEquity, last quarter 209.6m)
Debt / EBITDA = 0.53 (negative EBITDA) (Net Debt -36.3m / EBITDA -68.8m)
Debt / FCF = 0.81 (negative FCF - burning cash) (Net Debt -36.3m / FCF TTM -45.1m)
Total Stockholder Equity = 134.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.60% (Net Income -65.8m / Total Assets 231.3m)
RoE = -48.90% (Net Income TTM -65.8m / Total Stockholder Equity 134.6m)
RoCE = -48.37% (EBIT -69.9m / Capital Employed (Equity 134.6m + L.T.Debt 9.87m))
RoIC = -51.91% (negative operating profit) (NOPAT -69.9m / Invested Capital 134.6m)
WACC = 11.10% (E(919.5m)/V(929.4m) * Re(11.02%) + D(9.87m)/V(929.4m) * Rd(18.99%) * (1-Tc(-0.0)))
Discount Rate = 11.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 14.23%
Fair Price DCF = unknown (Cash Flow -45.1m)
EPS Correlation: 7.14 | EPS CAGR: 18.53% | SUE: 3.15 | # QB: 2
Revenue Correlation: 8.37 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.10 | Chg30d=+0.021 | Revisions Net=+2 | Analysts=7
EPS next Year (2026-12-31): EPS=-0.42 | Chg30d=+0.010 | Revisions Net=+4 | Growth EPS=+0.9% | Growth Revenue=+0.0%

Additional Sources for CMPX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle